Infections and Infectious Diseases | IND Enabling Drugs

Sanofi

Virtual Booth Sanofi Active Ingredient Solutions cover both APIs sales & CDMO.

FRANCE France

Contact Supplier

Virtual Booth

USP Workshop 2021

Participation Not Confirmed

Update your events

Sanofi and Translate Bio mRNA COVID-19 Vaccine Candidate Induced High Antibody Levels in Preclinical Studies

Lead Product(s): MRT5500

Therapeutic Area: Infections and Infectious Diseases Product Name: MRT5500

Highest Development Status: IND Enabling Product Type: Vaccine

Partner/Sponsor/Collaborator: Translate Bio

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable October 15, 2020

Details:

Preclinical evaluation of MRT5500, importantly, demonstrated a favorable immune response profile against SARS-CoV-2. These data support the selection of MRT5500 for clinical development.

Stemirna Therapeutics

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

CHINA China

Post An Enquiry

Virtual Booth

USP Workshop 2021

Participation Not Confirmed

Update your events

Stemirna COVID-19 Vaccine Candidate Obtains Clinical Trial Approval in China

Lead Product(s): mRNA Covid-19 vaccine

Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

Highest Development Status: IND Enabling Product Type: Vaccine

Partner/Sponsor/Collaborator: Tibet Rhodiola Pharmaceutical

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable January 05, 2021

Details:

The potential vaccine, which Stemirna has started working on since January last year, is based on messenger RNA (mRNA) technology, Tibet Rhodiola Pharma, which is jointly developing the candidate with Stemirna.